Breakthrough Study Suggests Hormone Treatment Could Target Root Cause of Chronic Back Pain

A hormone commonly used to treat osteoporosis may offer groundbreaking relief for millions suffering from chronic back pain, according to new research from Johns Hopkins University.

The study, published in the journal Bone Research, reveals that parathyroid hormone (PTH) could prevent and potentially reverse the abnormal nerve growth that causes persistent back pain – potentially shifting treatment approaches from simply managing symptoms to addressing the underlying condition.

Chronic back pain, a debilitating condition affecting millions worldwide, often stems from the deterioration of spinal discs and vertebral end plates – the thin tissue layers separating discs from vertebrae. As these structures break down, they become porous, allowing pain-sensing nerves to infiltrate areas where they don’t typically exist, resulting in chronic discomfort.

“During spinal degeneration, pain-sensing nerves grow into regions where they normally do not exist. Our findings show that parathyroid hormone can reverse this process by activating natural signals that push these nerves away,” explained Dr. Janet L. Crane, who led the Johns Hopkins research team.

The study’s findings are particularly promising because PTH is already FDA-approved for treating osteoporosis. Interestingly, some patients receiving the hormone for bone density issues have previously reported unexpected relief from back pain – a phenomenon this research may now explain.

Using animal models, researchers discovered that one to two months of PTH treatment led to denser, more stable vertebral endplates. More significantly, the treatment prompted bone-building cells called osteoblasts to produce a protein called Slit3, which effectively repels growing nerve fibers and prevents them from infiltrating sensitive regions of the spine.

To confirm the protein’s role, researchers removed Slit3 from the test subjects and found that the hormone’s pain-relieving effects disappeared, validating its critical function in the process.

The parathyroid glands naturally produce PTH, which plays a key role in regulating calcium levels and bone remodeling throughout the body. Synthetic versions have been used successfully for years to treat osteoporosis by increasing bone density in vulnerable patients.

This breakthrough comes at a critical time, as chronic back pain represents one of the leading causes of disability worldwide and drives billions in healthcare costs annually. Current treatments often focus on symptom management through pain medications, physical therapy, or surgical interventions rather than addressing the biological mechanisms causing the pain.

“Our study suggests that PTH treatment of lower back pain during spinal degeneration may reduce aberrant innervation,” Crane concluded, referring to the abnormal nerve growth that causes persistent pain.

The researchers acknowledge some limitations to their study. They note that PTH treatment could affect the central nervous system in ways not fully explored in this research. Additionally, because the study focused specifically on the Slit3 protein, further investigation is needed to determine how other genetic factors and bone-forming processes might influence spinal nerve growth and pain relief.

Despite these limitations, the findings lay a promising foundation for future clinical trials to explore PTH’s effectiveness as both a disease-modifying and pain-relieving treatment for spinal degeneration.

If successful in human trials, this approach could represent a paradigm shift in treating chronic back pain, offering hope to millions who currently rely on pain management strategies that address symptoms without tackling the root cause of their discomfort.

The study’s implications extend beyond back pain treatment, potentially offering new insights into nerve growth and pain mechanisms that could inform treatments for other chronic pain conditions.